NĒRx Biosciences was founded in 2009 by John Turchi, Ph.D, (President and CSO) and Robert Feltgen (CEO). Our pipeline of SMIs is based on the discoveries from Chief Scientific Officer Dr. John Turchi's lab at the Indiana University School of Medicine. His work in studying DNA damage and repair has dramatically advanced our understanding of genome instability and DNA repair in cancer treatment over the past two decades. The culmination of this academic research was the discovery of a series SMIs that inhibit DNA binding activity of our target proteins. NERx has an exclusive license to these and future discoveries from the Turchi lab and focuses on their clinical development and commercialization. Our ultimate goal is to develop novel therapeutics to enable the effective treatment of highly prevalent and difficult to treat cancers including lung and ovarian.